Gamma1 Heavy Chain Humanized (1-453) [Vh (Homo Sapiens Ighv1-3*01 (80.4%)--(Ighd) -Ighj3*01 (92.3%), Cdr-Imgt [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo Sapiens Ighg1*03V, G1M3>G1M17, Ng1M1, Ch1 K120, Ch3 E12, M14, G1V14 Ch2 1.3, A1.2 (Ch1 R120>K (220) (124-221) Hinge 1-15 (222-236), Ch2 L1.3>A (240), L1.2>A (241) (237-346), Ch3 E12 (362), M14 (364) (347-451), Chs (452-453))(124-453)], (226-213')-Disulfide With Kappa Light Chain Humanized (1'-213') [V-Kappa (Homo Sapiens Igkv3-11*01 (82.1%) -Igkj2*02 (100%), Cdr-Imgt [5.3.9] (27-31.49-51.88-96)) (1'-106') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')], Dimer (232-232'':235-235'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Glycoform Alfa
Cancer
Explore 1,379 assets in Cancer →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Elpiscience Biopharma, Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05075564CT.gov A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gamma1 Heavy Chain Humanized (1-453) [Vh (Homo Sapiens Ighv1-3*01 (80.4%)--(Ighd) -Ighj3*01 (92.3%), Cdr-Imgt [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo Sapiens Ighg1*03V, G1M3>G1M17, Ng1M1, Ch1 K120, Ch3 E12, M14, G1V14 Ch2 1.3, A1.2 (Ch1 R120>K (220) (124-221) Hinge 1-15 (222-236), Ch2 L1.3>A (240), L1.2>A (241) (237-346), Ch3 E12 (362), M14 (364) (347-451), Chs (452-453))(124-453)], (226-213')-Disulfide With Kappa Light Chain Humanized (1'-213') [V-Kappa (Homo Sapiens Igkv3-11*01 (82.1%) -Igkj2*02 (100%), Cdr-Imgt [5.3.9] (27-31.49-51.88-96)) (1'-106') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')], Dimer (232-232'':235-235'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Glycoform Alfa (this asset) | Elpiscience Biopharma, Ltd. | P1 | C · 39 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P4 | BB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Fluorouracilum | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | InSilico Medicine Hong Kong Limited | P4 | BB |
| Trametinib | Cancer Research UK | P2/3 | BB |
+42 more in the Cancer cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gamma1 Heavy Chain Humanized (1-453) [Vh (Homo Sapiens Ighv1-3*01 (80.4%)--(Ighd) -Ighj3*01 (92.3%), Cdr-Imgt [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo Sapiens Ighg1*03V, G1M3>G1M17, Ng1M1, Ch1 K120, Ch3 E12, M14, G1V14 Ch2 1.3, A1.2 (Ch1 R120>K (220) (124-221) Hinge 1-15 (222-236), Ch2 L1.3>A (240), L1.2>A (241) (237-346), Ch3 E12 (362), M14 (364) (347-451), Chs (452-453))(124-453)], (226-213')-Disulfide With Kappa Light Chain Humanized (1'-213') [V-Kappa (Homo Sapiens Igkv3-11*01 (82.1%) -Igkj2*02 (100%), Cdr-Imgt [5.3.9] (27-31.49-51.88-96)) (1'-106') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')], Dimer (232-232'':235-235'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Glycoform Alfa in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/gamma1-heavy-chain-humanized-1-453-vh-homo-sapiens-ighv1-301-804-ighd-ighj301-923-cdr-imgt-8816-26-3351-5897-112-1-123-homo-sapiens-ighg103v-g1m3g1m17-ng1m1-ch1-k120-ch3-e12-m14-g1v14-ch2-13-a12-ch1-r120k-220-124-221-hinge-1-15-222-236-ch2-l13a-240-l12a-241-237-346-ch3-e12-362-m14-364-347-451-chs-452-453124-453-226-213-disulfide-with-kappa-light-chain-humanized-1-213-v-kappa-homo-sapiens-igkv3-1101-821-igkj202-100-cdr-imgt-539-27-3149-5188-96-1-106-homo-sapiens-igkc01-100-km3-a451-152-v101-190-107-213-dimer-232-232235-235-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-lacking-the-glutamine-synthetase-gs-ko-gene-glycoform-alfa-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →